TED SC Placebo
Sponsors
Viridian Therapeutics S.à.r.l., Viridian Therapeutics Inc.
Conditions
Thyroid eye disease
Phase 3
VRDN-003-301: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with active thyroid eye disease (TED)
RecruitingCTIS2024-514972-42-00
Start: 2025-02-25Target: 54Updated: 2025-12-08
VRDN-003-302: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with chronic thyroid eye disease (TED)
Active, not recruitingCTIS2024-514973-23-00
Start: 2025-02-25Target: 91Updated: 2025-12-05
A randomized, double-masked, controlled, safety and tolerability study of VRDN-003 in participants with thyroid eye disease (TED)
Active, not recruitingCTIS2024-519417-57-00
Start: 2025-06-25Target: 76Updated: 2025-10-21